Abstract: Among the conventional processes for producing solid dispersion, the solid dispersion obtained by a solvent method is excellent in terms of solubility and bioavailability of a poorly soluble drug. However, due to frequent uses of organic solvents in the solvent method, problems have arisen such as organic solvent residue in products, environmental pollution and operational safety as well as corporate problems such as capital investment and the like required to avoid such events. The present invention provides a process for preparing pharmaceutical solid preparations without use of organic solvents frequently used in conventional solvent methods.

Abstract: Among the conventional processes for producing solid dispersion, the solid dispersion obtained by a solvent method is excellent in terms of solubility and bioavailability of a poorly soluble drug. However, due to frequent uses of organic solvents in the solvent method, problems have arisen such as organic solvent residue in products, environmental pollution and operational safety as well as corporate problems such as capital investment and the like required to avoid such events. The present invention provides a process for preparing pharmaceutical solid preparations without use of organic solvents frequently used in conventional solvent methods.

Abstract: Among the conventional methods for producing a solid dispersion, the solvent method is renowned for providing a solid dispersion that has improved solubility and bioavailability for poorly soluble drugs. However, the solvent method often uses volatile organic solvents such as dichloromethane, acetone and alcohol, causing problems such as the organic solvents remaining in the product, environmental pollution, workplace safety as well as the cost of the equipment necessary to avoid these concerns. Accordingly, a novel process is provided for preparing a solid dispersion without using the organic solvents often used in a conventional solvent method. That is, it is found that a solid preparation excellent in solubility can be obtained by carrying out a non-solvent coating method in which a core particle or particles are coated with an enteric coating agent and a plasticizer composition comprising a poorly soluble drug dissolved in a plasticizer.

Abstract: The present invention provides a low-substituted hydroxypropyl cellulose having a loose bulk density of not less than 0.40 g/mL and a tap bulk density of not less than 0.60 g/mL and a process for producing the same.

Abstract: Provided are a solid preparation which rapidly disintegrates in the oral cavity when taken together with the saliva in the oral cavity or a small amount of water, can be prepared easily and has strength enough to retain its formability upon production or during distribution; and a production process of the solid preparation. Specifically, provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater and a tapped bulk density of 0.60 g/ml or greater, and a sugar and/or sugar alcohol; and a production process of the solid preparation. Also provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a volume-average particle size as measured by the dry laser diffraction method of 25 &mgr;m or less which is obtained by pulverizing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater, a tapped bulk density of 0.

Abstract: Among the conventional processes for producing solid dispersion, the solid dispersion obtained by a solvent method is excellent in terms of solubility and bioavailability of a poorly soluble drug. However, due to frequent uses of organic solvents in the solvent method, problems have arisen such as organic solvent residue in products, environmental pollution and operational safety as well as corporate problems such as capital investment and the like required to avoid such events. The present invention provides a process for preparing pharmaceutical solid preparations without use of organic solvents frequently used in conventional solvent methods.

Abstract: The present invention provides a low-substituted hydroxypropyl cellulose having a loose bulk density of not less than 0.40 g/mL and a tap bulk density of not less than 0.60 g/mL and a process for producing the same.

Abstract: The present invention provides a low-substituted hydroxypropyl cellulose having a loose bulk density of not less than 0.40 g/mL and a tap bulk density of not less than 0.60 g/mL and a process for producing the same.

Abstract: Provided are a solid preparation which rapidly disintegrates in the oral cavity when taken together with the saliva in the oral cavity or a small amount of water, can be prepared easily and has strength enough to retain its formability upon production or during distribution; and a production process of the solid preparation. Specifically, provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater and a tapped bulk density of 0.60 g/ml or greater, and a sugar and/or sugar alcohol; and a production process of the solid preparation. Also provided are a solid preparation comprising a low-substituted hydroxypropyl cellulose having a volume-average particle size as measured by the dry laser diffraction method of 25 &mgr;m or less which is obtained by pulverizing a low-substituted hydroxypropyl cellulose having a loose bulk density of 0.40 g/ml or greater, a tapped bulk density of 0.

Abstract: A solid preparation characteristically containing for a binder methyl cellulose whose MeO content is 27.5-31.5 wt % and whose 2 wt % aqueous solution has a viscosity of 2-12 cP at 20° C. The present invention can provide a solid preparation which has an adequate hardness and at the same time disintegrates quickly for easy absorption.

Abstract: An antibacterial/antifungal inorganic matter is composited with wood by impregnating wood with a solution containing a silicon alkoxide and an antibacterial/antifungal organic silicon compound having a hydrolyzable alkoxysilyl group, and subjecting the silicon compounds within the cell walls (inter- and intracellular) spaces to hydrolysis at various temperatures and polycondensation. The same is prepared by treating wood with a siloxane oligomer and curing the oligomer. The antibacterial/antifungal component is prevented from being leached out.

Abstract: Wood is modified by impregnating wood with a methylsiloxane oligomer and heating the impregnated wood to cure the oligomer. The oligomer is of the average compositional formula: (CH.sub.3 SiO.sub.3/2).sub.m (MO.sub.3/2).sub.n or [CH.sub.3 SiO.sub.3/2 ].sub.x [(CH.sub.3).sub.a SiO.sub.(4-a)/2 ].sub.y [MO .sub.3/2 ].sub.z wherein M is P, PO and/or B, m and n are positive numbers with an average ratio of m:n ranging from 99:1 to 50:50, x, y, and z are positive numbers with an average ratio of (x+y):z ranging from 99:1 to 50:50 and an average ratio of x:y ranging from 99:1 to 50:50, and a is 2 or 3, and has a hydroxyl group and/or an alkoxyl group at a terminal end. This treatment of wood is safe. Since the methylsilicone resins thus incorporated and fixed within wood are not leached out in water, the modified wood maintains flame retardance for a very long time upon exposure to rain and dew and has water repellence, decay resistance and dimensional stability.